10 May 2019

JGL and Polpharma become strategic partners

Cross-licensing of prescription and non-prescription drugs, transfer of manufacturing of preservative free ophthalmic products, and potential collaboration on the Russian market – these are the key components of the partnership signed today by pharmaceutical companies JGL and Polpharma SA. Through the collaboration with Polpharma Group, being represented in 35 countries, products of the Croatian JGL will be available on the Polish and other European markets. In addition, a part of Polpharma’s portfolio will be manufactured in JGL's plants in Rijeka and sold on the Croatian and other European markets.

“We are very pleased about the partnership between our two great companies. This collaboration demonstrates JGL’s strength and competitiveness on the global market and competence of our employees, especially in the field of ophthalmology which is our core therapeutic area,” said Mislav Vučić, the CEO of JGL, who signed the contract with Markus Sieger, the CEO of Polpharma Group, at the headquarters of the Polish company.

“Polpharma has defined ophthalmology as one of our main growth therapeutic areas, where we have invested during the last few years in the development of new advanced products and industrial capabilities. Through yet another cooperation in ophthalmology, with JGL, we make our offer in this area even more compelling for our clients and patients. This will also allow us to enter new markets and expand our territory in the European Union. I believe that this is a great start of a very promising cooperation.” stated Markus Sieger.

Experts from both companies have already started the joint implementation of the agreed projects, with the first results of the cooperation already expected in the business year 2019.

About JGL:

JGL is a Croatian pharmaceutical company with a global reach and an innovative leader in the field of seawater nasal decongestants and ophthalmic drugs across the treatment spectrum. In the past 28 years, JGL has seen organic growth and international development. The company specialises in the development and production of value-added sterile products in ophthalmology and ENT, as well as the utilisation of seawater for health purposes.

With the opening of production facilities within the Pharma Valley complex in July 2015, JGL secured the prerequisites and capacities in development, production, and storage needed for the realisation of its long-term growth plans. Furthermore, JGL uses the Bag-on-Valve technology which positions it as one of the leading European manufacturers of sterile pharmaceutical forms – drops, sprays, and BoV systems. As a company dedicated to healthcare and the well-being of people, JGL is actively working on the development of new formulations and variations of products in all segments.

The JGL Group has 964 employees and operates in 50 markets, either directly or through its partners. JGL’s portfolio comprises 160 brands, 460 products, 1360 variations, and 6000 items, tailored to the needs of specific markets. The total revenue of the JGL Group in 2018 exceeded EUR 100 million, while in the first quarter of 2019, the company achieved the planned, double-digit growth in sales.

Read also

See all

Polpharma on its websites and mobile applications (“Website”) uses cookies and other related technologies (“cookies”). Self-management of cookies is possible by changing the settings in your web browser. If you do not agree to the collection of personal data through cookies, you can change the settings in your web browser or leave the Website.

By using the Website without changing the settings in your web browser, you accept Polpharma’s use of cookies. By accepting the settings in your web browser, you agree to profiling based on the information contained in cookies. Consent may be withdrawn at any time. Withdrawal of consent does not affect the lawfulness of the processing that was carried out on the basis of consent before its withdrawal.

More information can be found in the Cookies Policy.